A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Rivaroxaban (Xarelto, BAY59-7939) in Venous Thromboembolism, sponsored by Bayer. Completed at 109 sites in 28 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2020-04-01.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing rivaroxaban in Venous Thromboembolism — 18 open to participants now, 18 under way, 6 of them phase 3. Rivaroxaban · Venous Thromboembolism.
Among the 61 studies testing rivaroxaban in Venous Thromboembolism, this one is the 22nd largest by enrollment, is one of 3 that started in 2014, is one of 26 in phase 3, and was the 19th registered.
713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.
Browse Venous Thromboembolism studies →18 of the 61 studies testing rivaroxaban in Venous Thromboembolism are open now, in 12 countries. Recruiting first, the newest first:
Military Hospital of Tunis · Sites in Tunisia
Ages 18–80
Wolfson Medical Center · Sites in Israel
Ages 18–50 · Women only
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Thomas Jefferson University · Sites in United States
Ages 18+ · Women only
Medical University of Gdansk · Sites in Poland
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 29 · Phase 4 12
First in 2004; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 500 is above the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 272 across the 61 interventional studies. Of the 40 that completed or were terminated, 14 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 61 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
39 studies in Venous Thromboembolism by Bayer: 1 open now, 2 under way, none of them phase 3. Of 35 finished, 6 (17%) have results posted.
Among the 39 studies in Venous Thromboembolism by Bayer, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2014, is one of 10 in phase 3, and was the 21st registered.
Bayer’s Venous Thromboembolism studies by the year they started, since 2004.
8 of the studies testing rivaroxaban in Venous Thromboembolism that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05029063Phase 3Ottawa Hospital Research InstitutePrimary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters | 2026-12 |
| NCT07228663Phase 3McMaster UniversityHip Fracture Surgery Arterial and Venous Thrombotic Events Prevention | 2027-07-01 |
| NCT06580223Phase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | 2027-09-01 |
| NCT04874428Insel Gruppe AG, University Hospital BernDirect Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis | 2026-12 |
| NCT07907211Chen LijuanAspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 61 studies testing rivaroxaban in Venous Thromboembolism, from their registry updates:
Among Bayer’s 39 in Venous Thromboembolism:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For children younger than 6 months:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rivaroxaban (tablets and oral suspension) Dose: Age and body weight-adjusted dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban.
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Subcutaneous low molecular weight heparin (LMWH), subcutaneous fondaparinux and/or oral vitamin K antagonist (VKA) Dose : as per standard of care
Drug: Standard of Care
Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets
Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy. dose : as per standard of care
Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period
The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population
Time frame: During the main study treatment period (i.e., 3 months, except for children with central venous catheter venous thromboembolism (CVC-VTE) aged <2 years for whom it was 1 month)
Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period
The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population
Time frame: During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)
Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During Extended Treatment Period
Incidence rates for all children except those aged \< 2 years with catheter-related thrombosis. If no participant in the specific subgroup entered in the specific optional extension period, no analysis of an outcome was possible., The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference Population.
Time frame: During extended treatment period: up to month 12.
Number of Subjects With the Composite of All Symptomatic Recurrent Venous Thromboembolism During the 30 Days Post-study Treatment Period (i.e. >2 and ≤ 30 Days After Stop of Study Medication)
The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Age group with primary efficacy outcome was reported.
Time frame: More than 2 and up to 30 days after stop of study medication
Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period
The Central independent adjudication committee (CIAC) classified bleeding as: Major bleeding defined as overt bleeding and: · associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Clinically relevant non-major bleeding defined as overt bleeding not meeting the criteria for major bleeding, but associated with: medical intervention, or unscheduled contact (visit or telephone call) with a physician, or (temporary) cessation of study treatment, or discomfort for the child such as pain or impairment of activities of daily life (such as loss of school days or hospitalization).
Time frame: During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)
Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Extended Treatment Period
Incidence rates for all children except those aged \< 2 years with catheter-related thrombosis. If no participant entered in the specific optional extension period, no analysis of an outcome was possible. The CIAC classified bleeding as: Major bleeding defined as overt bleeding and: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Clinically relevant non-major bleeding defined as overt bleeding not meeting the criteria for major bleeding, but associated with: medical intervention, or unscheduled contact with a physician, or (temporary) cessation of study treatment, or discomfort for the child such as pain or impairment of activities of daily life.
Time frame: During extended treatment period: up to month 12.
Incidence Rates of the Composite of All Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging During the Main Treatment Period
The secondary efficacy outcome defined as the composite of all symptomatic recurrent venous thromboembolism and asymptomatic deterioration on repeat imaging as assessed by central independent adjudication committee. (CIAC) Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population
Time frame: During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)
AUC(0-24)ss in Plasma
AUC(0-24)ss: Area under the concentration vs. time curve from time 0 to 24 hours at steady state.
Time frame: over 24 hours
Cmax,ss in Plasma
Maximum drug concentration in measured matrix at steady state during a dosage interval
Time frame: 0 hours to 24 hours, 0 hours to 12 hours or 0 hours to 8 hours (one dosing interval in steady state)
Ctrough,ss in Plasma
Ctrough,ss refers to the drug concentration at the end of the dosage interval at steady state
Time frame: 0 hours to 24 hours, 0 hours to 12 hours or 0 hours to 8 hours(one sampling interval in steady state)
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
Time frame: Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
Time frame: Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
Time frame: Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.
Time frame: Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.
Time frame: Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
Time frame: Up to 3 hours post dose on Day30, and up to 6 hours post dose on Day 60
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
Time frame: Up to 3 hours post dose on Day30, and up to 6 hours post dose on Day 60
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
Time frame: Up to 3 hours post dose on Day30, and up to 6 hours post dose on Day 60
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.
Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.
Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
Time frame: Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
Time frame: Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
Time frame: Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60
Anti-Xa Values: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.
Time frame: Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 24 hours on Day 90
Anti-Xa Values: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.
Time frame: Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 24 hours on Day 90
Anti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.
Time frame: Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 16 hours on Day 90
Anti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.
Time frame: Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 16 hours on Day 90
Anti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.
Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Anti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.
Time frame: Up to 3 hours post dose on Day 30, up to 6 hours post dose on Day 60, and up to 16 hours on Day 90
Anti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.
Time frame: Up to 3 hours post dose on Day 30, up to 6 hours post dose on Day 60, up to 16 hours on Day 90 and follow-up up to 30 days
Anti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.
Time frame: Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60
Study was conducted at 109 study centers in 28 countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Finland, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Portugal, Russia, Singapore, Slovakia, Spain, Sweden, Switzerland, Turkey, UK, and USA between 13 Nov 2014 and 30 Jan 2019.
| Milestone | Rivaroxaban, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 | Comparator, Aged 12-<18 | Comparator, Aged 6-<12 | Comparator, Aged 2-<6 | Comparator, Aged 0.5-<2 | Comparator, Aged Birth-<0.5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 184 | 67 | 47 | 21 | 16 | 92 | 34 | 22 | 9 | 8 |
| Completed | 162 | 61 | 44 | 16 | 14 | 79 | 32 | 20 | 8 | 8 |
| Not completed | 22 | 6 | 3 | 5 | 2 | 13 | 2 | 2 | 1 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Efficacy outcome reached | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Patient convenience | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 1 | 1 | 0 | 0 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Recovery | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 4 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 5 | 1 | 1 | 3 | 2 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population
| Percentage of participants | Rivaroxaban Group | Comparator Group |
|---|---|---|
| Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period | 1.2 (0.4 to 3.0) | 3.0 (1.2 to 6.6) |
The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population
| Percentage of participants | Rivaroxaban, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 | Comparator, Aged 12-<18 | Comparator, Aged 6-<12 | Comparator, Aged 2-<6 | Comparator, Aged 0.5-<2 | Comparator, Aged Birth-<0.5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period | 2.2 ± 0.7 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 3.3 ± 0.9 | 2.9 ± 0.2 | 4.5 ± 0.2 | 0.0 ± 0.0 | 0.0 ± 0.0 |
Incidence rates for all children except those aged \< 2 years with catheter-related thrombosis. If no participant in the specific subgroup entered in the specific optional extension period, no analysis of an outcome was possible., The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference Population.
| Percentage of participants | Rivaroxaban, Aged 12-<18 | Comparator, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 | Comparator, Aged 6-<12 | Comparator, Aged 2-<6 | Comparator, Aged 0.5-<2 | Comparator, Aged Birth-<0.5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Extension 1 (month 3 to 6) | 0.0 (0.0 to 3.8) | 2.2 (0.1 to 10.9) | 0.0 (0.0 to 14.6) | 0.0 (0.0 to 16.3) | — | 0.0 (0.0 to 77.6) | 0.0 (0.0 to 14.6) | 0.0 (0.0 to 37.7) | 0.0 (0.0 to 95.0) | 0.0 (0.0 to 95.0) |
| Extension 2 (month 6 to 9) | 2.6 (0.1 to 13.4) | 5.3 (0.3 to 24.4) | 0.0 (0.0 to 29.9) | 0.0 (0.0 to 40.2) | — | — | 0.0 (0.0 to 63.2) | 0.0 (0.0 to 77.6) | — | — |
| Extension 3 (month 9 to 12) | 0.0 (0.0 to 11.6) | 0.0 (0.0 to 23.0) | 0.0 (0.0 to 63.2) | 0.0 (0.0 to 77.6) | — | — | 0.0 (0.0 to 95.2) | 0.0 (0.0 to 77.6) | — | — |
The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Age group with primary efficacy outcome was reported.
| Participants | Rivaroxaban, Aged 12-<18 | Comparator, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 | Comparator, Aged 6-<12 | Comparator, Aged 2-<6 | Comparator, Aged 0.5-<2 | Comparator, Aged Birth-<0.5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects With the Composite of All Symptomatic Recurrent Venous Thromboembolism During the 30 Days Post-study Treatment Period (i.e. >2 and ≤ 30 Days After Stop of Study Medication) | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The Central independent adjudication committee (CIAC) classified bleeding as: Major bleeding defined as overt bleeding and: · associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Clinically relevant non-major bleeding defined as overt bleeding not meeting the criteria for major bleeding, but associated with: medical intervention, or unscheduled contact (visit or telephone call) with a physician, or (temporary) cessation of study treatment, or discomfort for the child such as pain or impairment of activities of daily life (such as loss of school days or hospitalization).
| Percentage of participants | Rivaroxaban Group | Comparator Group |
|---|---|---|
| Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period | 3 (1.6 to 5.5) | 1.9 (0.5 to 3.3) |
The Central independent adjudication committee (CIAC) classified bleeding as: Major bleeding defined as overt bleeding and: · associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Clinically relevant non-major bleeding defined as overt bleeding not meeting the criteria for major bleeding, but associated with: medical intervention, or unscheduled contact (visit or telephone call) with a physician, or (temporary) cessation of study treatment, or discomfort for the child such as pain or impairment of activities of daily life (such as loss of school days or hospitalization).
| Percentage of participants | Rivaroxaban, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 | Comparator, Aged 12-<18 | Comparator, Aged 6-<12 | Comparator, Aged 2-<6 | Comparator, Aged 0.5-<2 | Comparator, Aged Birth-<0.5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period | 1.7 ± 0.5 | 3.0 ± 0.5 | 6.5 ± 1.8 | 4.8 ± 0.2 | 6.7 ± 0.3 | 2.2 ± 0.4 | 0.0 ± 0.0 | 0.0 ± 0.0 | 11.1 ± 0.6 | 0.0 ± 0.0 |
Incidence rates for all children except those aged \< 2 years with catheter-related thrombosis. If no participant entered in the specific optional extension period, no analysis of an outcome was possible. The CIAC classified bleeding as: Major bleeding defined as overt bleeding and: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Clinically relevant non-major bleeding defined as overt bleeding not meeting the criteria for major bleeding, but associated with: medical intervention, or unscheduled contact with a physician, or (temporary) cessation of study treatment, or discomfort for the child such as pain or impairment of activities of daily life.
| Percentage of participants | Rivaroxaban, Aged 12-<18 | Rivaroxaban, Aged 0.5-<2 | Comparator, Aged 12-<18 | Comparator, Aged 0.5-<2 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged Birth-<0.5 | Comparator, Aged 6-<12 | Comparator, Aged 2-<6 | Comparator, Aged Birth-<0.5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Extension 1 (month 3 to 6) | 1.1 (0.1 to 5.3) | — | 0.0 (0.0 to 6.9) | 0.0 (0.0 to 95.0) | 0.0 (0.0 to 14.6) | 0.0 (0.0 to 16.3) | 0.0 (0.0 to 77.6) | 0.0 (0.0 to 34.9) | 0.0 (0.0 to 37.7) | 0.0 (0.0 to 95.0) |
| Extension 2 (month 6 to 9) | 2.6 (0.1 to 13.4) | — | 5.3 (0.3 to 24.4) | — | 0.0 (0.0 to 29.9) | 0.0 (0.0 to 40.2) | — | 0.0 (0.0 to 63.2) | 0.0 (0.0 to 77.6) | — |
| Extension 3 (month 9 to 12) | 0.0 (0.0 to 11.6) | — | 0.0 (0.0 to 23.0) | — | 0.0 (0.0 to 63.2) | 0.0 (0.0 to 77.6) | — | 0.0 (0.0 to 95.0) | 0.0 (0.0 to 77.6) | — |
The secondary efficacy outcome defined as the composite of all symptomatic recurrent venous thromboembolism and asymptomatic deterioration on repeat imaging as assessed by central independent adjudication committee. (CIAC) Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population
| Percentage of participants | Rivaroxaban, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 | Comparator, Aged 12-<18 | Comparator, Aged 6-<12 | Comparator, Aged 2-<6 | Comparator, Aged 0.5-<2 | Comparator, Aged Birth-<0.5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Incidence Rates of the Composite of All Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging During the Main Treatment Period | 2.2 ± 0.7 | 0.0 ± 0.0 | 2.1 ± 0.1 | 0.0 ± 0.0 | 0.0 ± 0.0 | 4.3 ± 1.5 | 2.9 ± 0.2 | 4.5 ± 0.2 | 0.0 ± 0.0 | 0.0 ± 0.0 |
AUC(0-24)ss: Area under the concentration vs. time curve from time 0 to 24 hours at steady state.
| microgram*hour per liter | Rivaroxaban, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 |
|---|---|---|---|---|---|
| AUC(0-24)ss in Plasma | 2120 ± 26.4 | 1960 ± 31.7 | 2380 ± 40.7 | 1840 ± 36.4 | 1590 ± 29.6 |
Maximum drug concentration in measured matrix at steady state during a dosage interval
| microgram per liter | Rivaroxaban, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 |
|---|---|---|---|---|---|
| Cmax,ss in Plasma | 237 ± 20.6 | 184 ± 36.2 | 182 ± 31.2 | 136 ± 29.4 | 119 ± 24.1 |
Ctrough,ss refers to the drug concentration at the end of the dosage interval at steady state
| microgram per liter | Rivaroxaban, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 |
|---|---|---|---|---|---|
| Ctrough,ss in Plasma | 20.7 ± 45.8 | 21.4 ± 62.7 | 31.6 ± 70.1 | 22.9 ± 68.6 | 18.5 ± 50.4 |
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
| ratio | Rivaroxaban, Aged 12-<18 |
|---|---|
| Day 30 (0.5-1.5h) n=156 | 1.29 ± 0.28 |
| Day 30 (2.5-4h) n=150 | 1.57 ± 0.36 |
| Day 60 (2-8h) n=156 | 1.52 ± 0.29 |
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
| ratio | Rivaroxaban, Aged 6-<12 |
|---|---|
| Day 30 (0.5-1.5h) n=18 | 1.46 ± 0.25 |
| Day 30 (2.5-4h) n=20 | 1.67 ± 0.39 |
| Day 60 (2-8h) n=20 | 1.52 ± 0.33 |
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
| ratio | Rivaroxaban, Aged 6-<12 |
|---|---|
| Day 30 (0.5-1.5h) n=33 | 1.17 ± 0.23 |
| Day 30 (2.5-4h) n=33 | 1.26 ± 0.22 |
| Day 60 (2-8h) n=34 | 1.21 ± 0.19 |
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.
| ratio | Rivaroxaban, Aged 2-<6 |
|---|---|
| Day 30 (0.5-1.5h) n=1 | 0.99 ± NA |
| Day 30 (2.5-4h) n=34 | 1.36 ± 0.28 |
| Day 60 (2-8h) n=32 | 1.33 ± 0.26 |
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.
| ratio | Rivaroxaban, Aged 0.5-<2 |
|---|---|
| Day 30 (2.5-4h) n=1 | 1.41 ± NA |
| Day 60 (2-8h) n=2 | 1.05 ± 0.17 |
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
| ratio | Rivaroxaban, Aged 2-<6 |
|---|---|
| Day 30 (0.5-3h) n=4 | 1.87 ± 1.09 |
| Day 60 (2-6h) n=4 | 1.32 ± 0.12 |
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
| ratios | Rivaroxaban, Aged 0.5-<2 |
|---|---|
| Day 30 (0.5-3h) n=9 | 1.25 ± 0.18 |
| Day 60 (2-6h) n=7 | 2.00 ± 2.22 |
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.
| ratio | Rivaroxaban, Aged Birth-<0.5 |
|---|---|
| Day 30 (0.5-3h) n=11 | 1.35 ± 0.20 |
| Day 60 (2-6h) n=4 | 1.45 ± 0.16 |
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
| ratio | Rivaroxaban, Aged 12-<18 |
|---|---|
| Day 30 (0.5-1.5h) n=154 | 1.17 ± 0.28 |
| Day 30 (2.5-4h) n=149 | 1.38 ± 0.50 |
| Day 60 (2-8h) n=153 | 1.33 ± 0.38 |
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
| ratio | Rivaroxaban, Aged 6-<12 |
|---|---|
| Day 30 (0.5-1.5h) n=17 | 1.27 ± 0.20 |
| Day 30 (2.5-4h) n=17 | 1.39 ± 0.26 |
| Day 60 (2-8h) n=19 | 1.24 ± 0.20 |
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
| ratio | Rivaroxaban, Aged 6-<12 |
|---|---|
| Day 30 (0.5-1.5h) n=30 | 1.11 ± 0.24 |
| Day 30 (2.5-4h) n=30 | 1.15 ± 0.22 |
| Day 60 (2-8h) n=31 | 1.18 ± 0.24 |
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.
| ratio | Rivaroxaban, Aged 2-<6 |
|---|---|
| Day 30 (0.5-1.5h) n=1 | 0.90 ± NA |
| Day 30 (2.5-4h) n=32 | 1.29 ± 0.33 |
| Day 60 (2-8h) n=29 | 1.23 ± 0.21 |
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.
| ratio | Rivaroxaban, Aged 0.5-<2 |
|---|---|
| Day 30 (2.5-4h) n=1 | 1.13 ± NA |
| Day 60 (2-8h) n=2 | 1.10 ± 0.02 |
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
| ratio | Rivaroxaban, Aged 2-<6 |
|---|---|
| Day 30 (0.5-3h) n=4 | 1.50 ± 0.83 |
| Day 60 (2-6h) n=4 | 1.13 ± 0.06 |
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
| ratio | Rivaroxaban, Aged 0.5-<2 |
|---|---|
| Day 30 (0.5-3h) n=9 | 1.20 ± 0.39 |
| Day 60 (2-6h) n=6 | 1.10 ± 0.47 |
The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.
| ratio | Rivaroxaban, Aged Birth-<0.5 |
|---|---|
| Day 30 (0.5-3h) n=9 | 1.31 ± 0.15 |
| Day 60 (2-6h) n=3 | 1.21 ± 0.16 |
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.
| microgram per liter (mcg/L) | Rivaroxaban, Aged 12-<18 |
|---|---|
| Day 30 (0.5-1.5h) n=141 | 164.46 ± 124.46 |
| Day 30 (2.5-4h) n=164 | 254.66 ± 188.64 |
| Day 60 (2-8h) n=167 | 255.40 ± 171.59 |
| Day 90 (20-24h) n=58 | 62.12 ± 175.87 |
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.
| microgram per liter (mcg/L) | Rivaroxaban, Aged 6-<12 |
|---|---|
| Day 30 (0.5-1.5h) n=22 | 206.89 ± 105.01 |
| Day 30 (2.5-4h) n=23 | 263.24 ± 156.73 |
| Day 60 (2-8h) n=22 | 243.45 ± 124.92 |
| Day 90 (20-24h) n=9 | 27.39 ± 14.66 |
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.
| microgram per liter (mcg/L) | Rivaroxaban, Aged 6-<12 |
|---|---|
| Day 30 (0.5-1.5h) n=37 | 96.82 ± 76.77 |
| Day 30 (2.5-4h) n=36 | 139.10 ± 102.19 |
| Day 60 (2-8h) n=35 | 126.53 ± 81.78 |
| Day 90 (10-16h) n=20 | 47.49 ± 66.88 |
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.
| microgram per liter (mcg/L) | Rivaroxaban, Aged 2-<6 |
|---|---|
| Day 30 (2.5-4h) n=37 | 177.78 ± 147.29 |
| Day 60 (2-8h) n=36 | 150.03 ± 95.77 |
| Day 90 (10-16h) n=18 | 54.40 ± 51.52 |
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.
| microgram per liter (mcg/L) | Rivaroxaban, Aged 0.5-<2 |
|---|---|
| Day 30 (0.5-1.5h) n=1 | 247.54 ± NA |
| Day 30 (2.5-4h) n=2 | 160.71 ± 153.84 |
| Day 60 (2-8h) n=4 | 121.09 ± 81.94 |
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.
| microgram per liter (mcg/L) | Rivaroxaban, Aged 2-<6 |
|---|---|
| Day 30 (0.5-3h) n=4 | 209.67 ± 127.86 |
| Day 60 (2-6h) n=4 | 140.46 ± 78.82 |
| Day 90 (10-16h) n=1 | 62.56 ± NA |
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.
| microgram per liter (mcg/L) | Rivaroxaban, Aged 0.5-<2 |
|---|---|
| Day 30 (0.5-3h) n=12 | 111.35 ± 97.03 |
| Day 30 (2-6h) n=11 | 147.24 ± 125.40 |
| Day 90 (10-16h) n=3 | 23.40 ± 4.51 |
| Follow-up n=1 | 71.30 ± NA |
This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.
| microgram per liter (mcg/L) | Rivaroxaban, Aged Birth-<0.5 |
|---|---|
| Day 30 (0.5-3h) n=10 | 118.12 ± 82.08 |
| Day 60 (2-6h) n=5 | 228.03 ± 181.08 |
Collected over After randomization until last intake of study medication plus 2 days, up to 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Comparator Group | 0/162 (0%) | 35/162 (21.6%) | 121/162 (74.7%) |
| Rivaroxaban Group | 2/329 (0.6%) | 78/329 (23.7%) | 275/329 (83.6%) |
| Event | Comparator Group | Rivaroxaban Group |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/162 | 8/329 |
| HeadacheNervous system disorders | 3/162 | 2/329 |
| VomitingGastrointestinal disorders | 0/162 | 6/329 |
| PyrexiaGeneral disorders | 2/162 | 6/329 |
| SeizureNervous system disorders | 2/162 | 1/329 |
| Abdominal painGastrointestinal disorders | 1/162 | 3/329 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/162 | 3/329 |
| PancytopeniaBlood and lymphatic system disorders | 1/162 | 0/329 |
| Sickle cell anaemia with crisisBlood and lymphatic system disorders | 1/162 | 0/329 |
| Atrial tachycardiaCardiac disorders | 1/162 | 0/329 |
| Event | Comparator Group | Rivaroxaban Group |
|---|---|---|
| HeadacheNervous system disorders | 24/162 | 56/329 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 20/162 | 40/329 |
| PyrexiaGeneral disorders | 14/162 | 37/329 |
| VomitingGastrointestinal disorders | 13/162 | 36/329 |
| NasopharyngitisInfections and infestations | 10/162 | 29/329 |
| DiarrhoeaGastrointestinal disorders | 11/162 | 25/329 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 9/162 | 23/329 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/162 | 18/329 |
| NauseaGastrointestinal disorders | 6/162 | 22/329 |
| FatigueGeneral disorders | 6/162 | 21/329 |
| Age, Customized(Participants) | Rivaroxaban, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 | Comparator, Aged 12-<18 | Comparator, Aged 6-<12 | Comparator, Aged 2-<6 | Comparator, Aged 0.5-<2 | Comparator, Aged Birth-<0.5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12-<18 years | 184 | 0 | 0 | 0 | 0 | 92 | 0 | 0 | 0 | 0 | 276 |
| 6-<12 years | 0 | 67 | 0 | 0 | 0 | 0 | 34 | 0 | 0 | 0 | 101 |
| 2-<6 years | 0 | 0 | 47 | 0 | 0 | 0 | 0 | 22 | 0 | 0 | 69 |
| 0.5-<2 years | 0 | 0 | 0 | 21 | 0 | 0 | 0 | 0 | 9 | 0 | 30 |
| Birth-<0.5 years | 0 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 0 | 8 | 24 |
| Sex: Female, Male(Participants) | Rivaroxaban, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 | Comparator, Aged 12-<18 | Comparator, Aged 6-<12 | Comparator, Aged 2-<6 | Comparator, Aged 0.5-<2 | Comparator, Aged Birth-<0.5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 97 | 24 | 24 | 10 | 5 | 55 | 15 | 9 | 5 | 1 | 245 |
| Male | 87 | 43 | 23 | 11 | 11 | 37 | 19 | 13 | 4 | 7 | 255 |
| Ethnicity (NIH/OMB)(Participants) | Rivaroxaban, Aged 12-<18 | Rivaroxaban, Aged 6-<12 | Rivaroxaban, Aged 2-<6 | Rivaroxaban, Aged 0.5-<2 | Rivaroxaban, Aged Birth-<0.5 | Comparator, Aged 12-<18 | Comparator, Aged 6-<12 | Comparator, Aged 2-<6 | Comparator, Aged 0.5-<2 | Comparator, Aged Birth-<0.5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 164 | 58 | 42 | 15 | 12 | 79 | 26 | 19 | 8 | 6 | 429 |
| Not Hispanic or Latino | 7 | 5 | 1 | 3 | 1 | 6 | 5 | 1 | 0 | 0 | 29 |
| Unknown or Not Reported | 13 | 4 | 4 | 3 | 3 | 7 | 3 | 2 | 1 | 2 | 42 |
Showing the first 100 of 109 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2014 to primary completion in Jan 2019, 50 months.
Results were first posted in Apr 2020, 1 year 2 months after primary completion.
Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 50 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban